Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC Filings

SEC Filings

Filing date	Form	Description	View
Apr 29, 2020	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0001558370-20-004641.pdf 0001558370-20-004641.rtf 0001558370-20-004641.xls
Apr 21, 2021	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0001558370-21-004559.pdf 0001558370-21-004559.rtf 0001558370-21-004559.xls
Apr 29, 2022	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0001558370-22-006383.pdf 0001558370-22-006383.rtf 0001558370-22-006383.xls
Apr 28, 2023	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0001558370-23-007344.pdf 0001558370-23-007344.rtf 0001558370-23-007344.xls
Apr 10, 2015	S-1/A	Amended Registration statement for face-amount certificate companies	View HTML 0001047469-15-003351.pdf 0001047469-15-003351.rtf 0001047469-15-003351.xls
Apr 20, 2015	S-1/A	Amended Registration statement for face-amount certificate companies	View HTML 0001047469-15-003668.pdf 0001047469-15-003668.rtf 0001047469-15-003668.xls
Aug 01, 2018	10-K/A	Amendment to a previously filed 10-K	View HTML 0001558370-18-006096.pdf 0001558370-18-006096.rtf 0001558370-18-006096.xls
Jul 22, 2016	10-Q/A	Amendment to a previously filed 10-Q	View HTML 0001558370-16-006732.pdf 0001558370-16-006732.rtf 0001558370-16-006732.xls
Aug 01, 2018	10-Q/A	Amendment to a previously filed 10-Q	View HTML 0001558370-18-006098.pdf 0001558370-18-006098.rtf 0001558370-18-006098.xls
Jun 30, 2017	4/A	Amendment to a previously filed 4	View HTML 0001179110-17-009848.pdf 0001179110-17-009848.rtf 0001179110-17-009848.xls

Continue